Brugada syndrome (BrS), one of the most common causes of sudden cardiac death (SCD) in normal structural heart individuals, is a young entity in modern medicine. BrS was first characterised in 1992 by Brugada et al. as a distinct syndrome with "right bundle branch block, persistent ST elevation in precordial leads V1 to V2-3 and sudden cardiac death".
of BrS ( Figure 1A) . 9 Subsequently, Hu et al. studied 150 unrelated BrS patients and used direct gene sequencing to identify 17 SCN10A mutations in 25 of these patients (16.7%). The identification of SCN10A
as a susceptibility gene in this study improved the yield of genotype testing from <35% to >50% of BrS probands. 10 However, the monogenic causative role of SCN10A in BrS was questioned by other groups. 11, 12 BrS was previously considered a rare disease of single-gene
Mendelian inheritance until a genome-wide association study in 2013 demonstrated the strong effect of common genetic variations and polymorphisms on BrS. 9 Not only were three common genetic variants (SCN5A, SCN10A and HEY2) identified from the study as modulators for BrS susceptibility, but the risk of BrS also progressively increased in association with the escalating total number of alleles at the three associated loci.
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Models for Pathophysiology
There are three major mechanistic models explaining the electric abnormality in BrS, namely the repolarisation, depolarisation and neural crest models. [13] [14] [15] Despite their differences, all three models agree that the major region of pathology is the right ventricular outflow tract (RVOT). [13] [14] [15] Commonly considered as a channelopathy, evidence has revealed structural derangement of the right ventricle in BrS. Using cardiac MRI, BrS patients were found to have right ventricular (RV) motion abnormalities with mildly reduced systolic function and mildly increased RV end systolic volume, compared with normal individuals. 16, 17 Although late gadolinium enhancement was not detected in cardiac MRI, histological evidence of substantial fibrosis in the RVOT epicardium, corresponding to a low expression of Cx43, was found in the hearts (from autopsy or explanted hearts)
of BrS individuals. 18 Epicardial and interstitial fibrosis was identified in the slow-conducting RVOT region, 18 the ablation of which abolished the BrS ECG pattern. 19 A recent study has further shown that RVOT electroanatomical alterations (a low-voltage area) correlate with myocardial inflammation and arrhythmia vulnerability, supporting the hypothesis that BrS is a combination of electrical and structural disease. 20 Furthermore, a phenotypic overlap between arrhythmogenic right ventricular cardiomyopathy and BrS has been reported in the literature. RV changes consistent with arrhythmogenic right ventricular cardiomyopathy were observed in patients with clinically diagnosed
BrS. 21 The concept of the connexome connects the two diseases. 22 The connexome is comprised of structures including desmosomes, fascia adherence junctions, gap junctions and voltage-gated sodium channels at the cardiomyocyte intercalated disc ( Figure 1B ). 22 Accumulating evidence has shown that these structures are closely interconnected and interdependent for anchorage and stabilisation.
For instance, a mutation in PKP2 -the most important gene responsible for arrhythmogenic right ventricular cardiomyopathy -directly leads to a reduction in Na v 1.5 trafficking and activity; 23 Cx43 is required for Na v 1.5 stability in the intercalated disk membrane. 24 Therefore, sodium channel activity could be affected by the disruption of any connexome components.
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Update on Clinical Diagnosis
A recent change in the BrS phenotype at presentation compared with earlier years (prior to 2003) has been noted. 25 There is a decreased number of patients presenting with aborted SCD, spontaneous type 1 ECG pattern and arrhythmia inducibility during electrophysiology study (EPS), whereas the prevalence of syncope remains stable. 25 This shift to a milder clinical profile is likely owing to better identification and thus improved diagnosis of BrS.
The diagnostic criteria have been updated in the 2013 consensus statement by the Heart Rhythm Society (HRS), the European Heart Rhythm Association (EHRA) and the Asia Pacific Heart Rhythm Society (APHRS). 26 Contrary to the prior 2005 HRS/EHRA criteria, the 2013 HRS/ EHRA/APHRS consensus statement has listed several differences. protocol (two sites and up to three extrastimuli). 49 Quinidine was able to prevent VF induction in 52 of the 58 (89.6%) patients tested. During a median follow-up of 113 months, the overall annual arrhythmic events were 1%. However, the caveats of this study included an aggressive stimulation protocol and low long-term medication adherence (60%), due to side-effects. 49 Low tolerance and medication adherence caused by the sideeffects of quinidine have been a concern. It has been shown that the risk of arrhythmic events in quinidine recipients was associated with medication interruption. 40, 49 Side-effects are reported to be as high as 36-38% of patients administered a daily dose of quinidine bisulfate (QBS) 1,500 mg or hydroquinidine (HQC) 900 mg. 39, 49 Medication discontinuation was reported at 14-30% due to medication intolerance. 41, 49 Diarrhoea is the most common adverse effect (9-18%), and other side-effects include thrombocytopenia (6.6-13.6%), and less commonly allergic reactions (<5%), oesophagitis (<5%), side node dysfunction (<5%) and lupus-like reactions (<5%).
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QTc prolongation was often observed (the change by percentage was reported from <10% to 15.8%); however, torsades de pointes was not reported. [47] [48] [49] [50] A lower dosage (daily HQC dose 600 mg) appears to be better tolerated. 50, 51 Further lower dosages (QBS or HQC ≤600 mg) have been reported to reduce side-effects while maintaining efficacy; 52 however, concerns exist regarding the reduced suppression of VF inducibility and possible compromised anti-arrhythmic effects at doses lower than 600 mg. 51 Despite great efficacy in treating BrS, quinidine is currently an endangered species due to the shrinking pharmaceutical market for quinidine in the era of newer anti-arrhythmic medications for common cardiac arrhythmias. AstraZeneca was the main quinidine manufacturer, but stopped production in 2006. According to a survey of physicians in 131 countries, limited access to quinidine was reported in 76% of countries (including Thailand and the Philippines, where BrS has a high prevalence). 53 Even in the US, where quinidine is still produced, it is not readily available in many healthcare facilities.
The use of isoproterenol infusion is a class IIb recommendation for electrical storm in BrS patients. 26 Other oral medications suggested as long-term alternatives to quinidine have been explored. Cilostazol, bepridil and denopamine, alone or combined, have been reported to prevent VF storm in BrS patients in clinical cases after initial stabilisation with isoproterenol. [54] [55] [56] Cilostazol, an inhibitor of phosphodiesterase III, increases inward the calcium current and suppresses the I to current by increasing heart rate. Case reports have demonstrated its efficacy in suppressing recurrent VF and VT. 57, 58 However, its failure to suppress VF storm in BrS patients has also been reported. 59, 60 Bepridil is a multichannel blocker that inhibits L-and T-type calcium channels, as well as all potassium channels.
Aizawa et al. reported the efficacy of bepridil efficacy in suppressing recurrent VF in five BrS patients (a total of 19 shocks were given 45 Reproduced with permission from Oxford University Press.
Spontaneous type 1
Patients at risk in a year before bepridil and two shocks while on bepridil). 56 The combination of bepridil and cilostazol has been proposed for its possible synthetic effects in VF prevention and the attenuation of cilostazol-induced palpitations. 55 This regimen was shown to effectively suppress recurrent VF and ICD shocks in five BrS patients (13 ICD shocks in total in an accumulated period of 55 months before medication, and 0 shocks in an accumulated 272 months while on medication). 55 Despite the promising results, the numbers of patients in these studies are low, with relatively short follow-up periods. Direct comparison with quinidine has also not been studied. Future studies are needed to further address these issues.
Radiofrequency Ablation
Radiofrequency ablation (RFA) has arisen as a promising therapeutic and thus epicardial ablation has become a more accepted approach due to its improved efficacy in eliminating arrhythmogenic substrates.
A recent meta-analysis including 11 case series and 11 case reports (total number of patients: 233) has provided a systemic overview on the evidence of RFA in BrS. 67 A comparison was made between the following ablation strategies: epicardial mapping with substrate ablation (n=180), endocardial-only mapping with ablation (n=17), VF-triggering PVC ablation (n=5) and mixed approaches (n=30).
Elimination of type 1 Brugada ECG pattern was achieved in 98.3%
of the epicardial approach groups versus 34.8% in the endocardial approach. 67 The success rates in preventing VT/VF were 96.7%, 70.6%
and 80.0% in epicardial, endocardial and triggering PVC ablation strategies, respectively. Table 2) . 19 
Substrate Mapping and the Use of Sodium Channel Blockers
Endocardial and epicardial electroanatomic mapping of RV is widely performed in order to identify the substrate in BrS patients. 19, 36, [64] [65] [66] 68, 69 Notably, in patients undergoing both epicardial and endocardial mapping, no endocardial substrate was identified in 93% of cases. have been utilised in different studies ( Table 2 ). Procainamide appears to increase the substrate to a lesser extent than ajmaline. 19 There is no direct comparison between ajmaline and flecainide. However, in diagnosing the drug-induced type 1 ECG pattern, a higher sensitivity of ajmaline (1 mg/kg × 5 min) over flecainide (2 mg/kg × 5 min) was reported.
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Attenuation of Brugada Syndrome Phenotype by General Anaesthesia
An observation of the effect of general anaesthesia on BrS phenotype during RFA in BrS patients was recently reported. . 65 This study has demonstrated a significant clinical implication in assessing the substrate area during RFA under anaesthesia.
Efficacy of the Radiofrequency Ablation Procedure
Technical advances in ablating catheters might have improved the efficacy of substrate elimination. 19 A contact force of at least 5 g is recommended to effectively ablate lesions with a radiofrequency power of 20-45 W. 19 The electrogram voltage amplitude drastically decreases during RFA. The reduction of voltage to <0.5 mV (dense scar tissue), with the disappearance of the mid and late components of fractionated potentials, indicates the elimination of the arrhythmogenic substrate ( Figure 5 ). 19, 64 In studies conducted thus far, various tests have been utilised as evidence of successful ablation, including normalisation of type 1 ECG pattern ( Figure 6B) , abolishment of VT/VF inducibility and elimination of substrate in remapping ( Figure 5) . Persistent or recurrent J-ST elevation has been shown to be associated with recurrence of VT/ VF after RFA. 67 In a 2017 report by Nademanee et al., the authors recommended eliminating all substrate areas with abnormal lowvoltage and fractionated electrograms, confirmed by repeat substrate mapping, rather than using VT/VF inducibility or ECG normalisation as the end points for epicardial ablation. 19 
Ongoing Clinical Trials
Despite various studies reporting on the success of epicardial ablation with low recurrence of VT/VF, the sample sizes in most of these studies V1 II  V2 II  V1 III  V2 III  V1 IV  V2 IV   I   II  III   aVR  aVL  aVF   V1 II  V2 II  V1 III  V2 III  V1 IV  V2 IV   I  II  III   aVR  aVL  aVF   V1 II  V2 II   V1 III  V2 III  V1 IV  V2 IV are small. Additionally, the lack of control groups, different protocols 
Clinical Perspective
• The complexity of Brugada syndrome (BrS) continues to evolve, and therefore understanding the mechanisms of this disease is imperative to provide better alternatives for treatment.
• Early detection and risk stratification are areas of major importance in the treatment of BrS.
• Radiofrequency ablation of RVOT substrate has arisen as a promising treatment modality for BrS, although larger scale and long-term follow-up studies are required to further determine its merit. I  II  III  aVR  aVL  aVF  V1 II  V2 II  V1 III  V2 III  V1 IV  V2 IV   I  II  III  aVR  aVL  aVF  V1  V2  V3  V4  V5  V6   I  II  III  aVR  aVL  aVF  V1 II  V2 II  V1 III  V2 III  V1 IV  V2 IV 
